Stockscreener 앱 받기
44.28
3.45%
-1.58
시간 외 거래:
44.32
0.04
+0.09%
전일 마감가:
$45.86
열려 있는:
$45.95
하루 거래량:
2.19M
Relative Volume:
0.81
시가총액:
$11.50B
수익:
$2.32B
순이익/손실:
$782.57M
주가수익비율:
15.91
EPS:
2.7838
순현금흐름:
$875.84M
1주 성능:
+0.18%
1개월 성능:
+7.37%
6개월 성능:
+10.62%
1년 성능:
+21.18%
1일 변동 폭
$44.00
$46.10
1주일 범위
$43.75
$46.10
52주 변동 폭
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.28 | 11.91B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
EXEL | Exelixis Inc Executive Compensation - Quiver Quantitative
EXELIXIS, INC. ($EXEL) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay and equity plan on ballot at Exelixis (NASDAQ: EXEL) 2026 meeting - Stock Titan
Exelixis: Stable Demand And High Margins With Undervalued Shares (NASDAQ:EXEL) - Seeking Alpha
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators - Markets Mojo
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Working capital per share of Exelixis, Inc. – BX:EX9 - TradingView — Track All Markets
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference - Yahoo
EXELAnnual Report (10-k) - ADVFN
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - ADVFN
Neuroendocrine Tumor Treatment Market size to cross $5.12 - openPR.com
How (EXEL) Movements Inform Risk Allocation Models - Stock Traders Daily
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)? - Sahm
Stock Report: Can Exelixis Inc sustain its profitability2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Nisa Investment Advisors LLC Has $6.16 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Tema Etfs LLC Grows Position in Exelixis, Inc. $EXEL - MarketBeat
Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Moving Averages: Is Exelixis Inc a play on infrastructure spendingGlobal Markets & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Eastern Progress
Exelixis: A Strong Contender in the Cancer Drug Market - The Globe and Mail
Kidney Cancer Drugs Market to Grow by $2 Billion During - GlobeNewswire
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Trading Systems Reacting to (EXEL) Volatility - Stock Traders Daily
Exelixis, Inc. $EXEL Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
RBC Capital lowers Exelixis (EXEL) price target to $43 - MSN
MIC:EXEL-RM OCF Yield %: 8.20 — 52% Above Median - GuruFocus
Exelixis, Inc. $EXEL Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 - Insider Monkey
15 Set-It-and-Forget-It Stocks to Buy in 2026 - Insider Monkey
Exelixis (MIC:EXEL-RM) NonCurrent Deferred Revenue : ₽0.00 Mil (As of Dec. 2025) - gurufocus.com
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
EXEL Financials: Income Statement, Balance Sheet & Cash Flow | Exelixis Inc - Stock Titan
Vanguard disaggregates holdings; Exelixis (NASDAQ: EXEL) shows 0 shares - Stock Titan
Exelixis (NASDAQ:EXEL) Raised to Strong-Buy at Truist Financial - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by Nordea Investment Management AB - MarketBeat
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
EXEL Stock Price, Quote & Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):